Executives Team

Engage Therapeutics was founded by Greg Mayes, President and CEO; and Jouko Isojarvi MD, PhD Executive Vice President and Chief Medical Officer. Engage’s founders bring a combination of strong biopharma pedigrees and personal, family connections to epilepsy. Greg’s son has epilepsy, while Jouko has spent his entire career taking care of epilepsy patients as well as developing and commercializing approved treatments for this condition.

Gregory T. Mayes
President, Chief Executive Officer and Founder

Greg, a biopharma leader for more than 20 years, has been personally affected by epilepsy. After years of absence seizures, which often precede epilepsy, his son Conner was diagnosed with epilepsy in 2014. Greg is dedicated to leveraging his drug development experience and working with key opinion leaders (KOLs) to identify new therapeutic options for patients affected by epilepsy. He, along with his team of KOLs, believe they have finally found that option with Staccato Alprazolam.

Prior to founding Engage Therapeutics, Greg played an integral role in the growth of Advaxis Immunotherapies, a Princeton, N.J., based biotech company developing immuno-oncology therapies for patients with hard-to-treat cancers through its bacterial vector system, Lm Technology™. As its chief operating officer, he was instrumental in helping to secure more than $200 million in funding and in identifying and negotiating partnerships with companies such as Amgen, AstraZeneca and Merck & Co., Inc.

Greg also served as a president of Unigene Laboratories, Inc. As ImClone’s general counsel, Greg played a key role in managing multiple clinical and regulatory activities that led to the 2008 acquisition by Eli Lilly for $6.5 billion. Earlier in his career, Greg was responsible for providing legal advice to the AstraZeneca oncology franchise as senior counsel and he started his biopharma legal career at the national law firm of Morgan Lewis.

Greg earned his bachelor of science from Syracuse University and his JD from Temple University School of Law.

Jouko Isojarvi MD, PhD
Executive Vice President, Chief Medical Officer and Founder

Jouko IsojarviJouko, a veteran physician of 35 years, has dedicated much of his career to epilepsy patients as a clinician caring for patients and families and a researcher and investigator on numerous international clinical trials for antiepileptic drugs including a LAMICTAL® (lamotrigine), a well-known treatment for epilepsy.

Prior to launching Engage Therapeutics, Jouko was senior medical director at Lundbeck, where he was responsible for medical oversight and post approval development of epilepsy products including SABRIL® (vigabatrin) and ONFI® (clobazam). He oversaw the optimal and safe use of the drugs, working closely with advocacy groups including the Epilepsy Foundation.

Before his time at Lundbeck, Jouko served in leadership roles at UCB Pharma within the epilepsy team for the clinical development of VIMPAT® (lacosamide). He played a key role in designing, implementing and completing clinical trials for phases 3-4 and served as medical lead for the VIMPAT® (lacosamide) monotherapy programs for partial onset seizures in the United States and Europe. He was also the lead for the VIMPAT® (lacosamide) generalized tonic-clonic seizures program. Jouko also served as medical and clinical lead for the BRIVIACT® (brivaracetam) program in idiopathic generalized seizures. In his role at UCB he served as the medical expert in all interactions with U.S and EU regulatory authorities.

Prior to that, Jouko served as head of the neurology group in clinical development at Jazz Pharmaceuticals, where he played an integral role in the development of JZP-8 (intranasal clonazepam) for acute repetitive seizures and JZP-4 (a lamotrigine-like compound) for partial onset seizures. At GlaxoSmithKline, Jouko was director in clinical development and medical affairs for LAMICTAL® (lamotrigine), where he was scientific and clinical lead.

He received his MD and PhD from the University of Oulu in Finland, where he served at the helm of the Epilepsy Research Group for nearly 10 years.